Palvella Therapeutics, Inc. Contract with Customer, Liability, Noncurrent
Palvella Therapeutics, Inc. (PVLA) had Contract with Customer, Liability, Noncurrent of $0 as of 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent › Deferred Revenue, Noncurrent
us-gaap:ContractWithCustomerLiabilityNoncurrent · last filed 2024-03-29
- 2023-12-31: Contract with Customer, Liability, Noncurrent $0.00.
- 2023-09-30: Contract with Customer, Liability, Noncurrent $0.00.
- 2023-06-30: Contract with Customer, Liability, Noncurrent $759.00K.
- 2023-03-31: Contract with Customer, Liability, Noncurrent $11.73M.
| Period end | Contract with Customer, Liability, Noncurrent |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-29 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-14 |
| 2023-06-30 | $759.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $11.73M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $18.73M 10-K · filed 2024-03-29 |
| 2022-09-30 | $18.48M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $22.06M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $30.82M 10-Q · filed 2022-05-11 |
| 2021-12-31 | $38.40M 10-K · filed 2023-03-31 |
| 2021-09-30 | $46.19M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $49.42M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $32.31M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $35.90M 10-K · filed 2022-03-02 |
| 2020-09-30 | $36.92M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $37.84M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $38.56M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $47.26M 10-K · filed 2021-03-31 |
| 2019-09-30 | $44.18M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $58.11M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $59.73M 10-Q · filed 2019-05-10 |
| 2019-01-01 | $56.78M 10-K · filed 2020-03-13 |
| 2018-12-31 | $53.30M 10-K · filed 2020-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |